https://www.selleckchem.com/pr....oducts/trastuzumab-d
The 6-month survival rate was 66.7%, compared to a 1-year survival rate of 25.0%, with a median overall survival time was 10.5 months. Kaplan-Meier analysis showed that the comprehensive treatment was superior to radiotherapy and/or chemotherapy (P=0.003). Conclusions PSCCT is a rare type of thyroid cancer that is highly invasive and has a poor prognosis. We show that a comprehensive treatment plan can significantly improve patient survival. 2019 Gland Surgery. All rights reserved.Background The objective of this study wa
Like
Comment
Share
